Now Enrolling!

CYGNET: A Natural History Study of Adult Men with Adrenomyeloneuropathy (AMN)

A Prospective, Retrospective, Multicenter, Observational Study of Disease Progression in Adults with Inherited Forms of Spastic Paraplegia

Why should I be interested in the CYGNET Study?

"Natural history" studies follow people who have, or are at risk of developing, a specific medical condition. They collect health information to understand how the condition or disease develops and how to treat it.

The CYGNET study is a natural history study of patients with AMN designed to increase our knowledge of AMN-related disabilities and inform the design of future clinical studies of potential treatments.

The study will use new methods, such as wireless sensors, in addition to traditional approaches.

Who can participate?

Some of the criteria participants must meet include:

- Men aged 18 years and older, diagnosed with AMN
- Clinical evidence of spinal cord involvement but still able to walk

Individuals with evidence of cerebral inflammatory disease, which may occur with AMN, cannot participate.

What is expected of me if I participate?

The study will last 2 years, during which you will have:

- 3 in person clinic visits (beginning, middle, and end of study)
- Periodic telemedicine visits

There will be no investigational treatment. Your doctor will continue to provide your usual ongoing care. Study participants will undergo physical and neurological exams, answer questionnaires, and wear a special watch to monitor activity, sleep, and symptoms such as changes in gait and balance.

Where will the study take place? How can I learn more?

If you are interested, please contact clinicaltrials@swanbiotx.com, call (267) 417-6356, or go to www.clinicaltrials.gov:NCT05008874.

About SwanBio Therapeutics

SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, genetically defined neurological conditions. We are advancing a pipeline of AAV-based gene therapies, designed to be delivered intrathecally, to address targets within both the central and peripheral nervous systems. Our lead program is being advanced toward clinical development for the treatment of adrenomyeloneuropathy (AMN).

SwanBio THERAPEUTICS

www.swanbiotx.com